US Q2 2026 Earnings: Staar Surgical Revenue Surges 111% on China Demand; Spruce Power Returns to Profit

The Quick Take

• Staar Surgical Q2 2026 net sales surge 111% YoY to $93.5M driven by strong China demand for EVO Plus lenses
• Spruce Power returns to positive net income and higher EBITDA despite going concern disclosure for debt maturities
• Staar EVO Plus China demand validates premium phakic IOL market expansion in Asia's largest vision care market
• Spruce Power solar asset operating EBITDA improvement signals residential solar lease business recovery

Staar Surgical Company delivered a standout Q2 2026 performance with net sales surging 111% year-over-year to $93.5 million, driven by robust demand in China for its EVO Plus implantable collamer lens — a premium phakic intraocular lens that corrects refractive errors without removing the natural lens, offering a reversible alternative to LASIK surgery for myopic patients. The result demonstrates that China's premium ophthalmology market — one of the world's largest given the extreme myopia prevalence among Chinese young adults — is rebounding from the post-2022 consumption slowdown at a pace that has exceeded analyst expectations. Staar Surgical's ability to sustain this trajectory depends on Chinese consumer confidence in elective medical procedures and the competitive environment from domestic Chinese phakic IOL producers who are developing competing products at lower price points.

In the clean energy segment, Spruce Power Holding returned to positive net income in Q2 2026 while posting improved operating EBITDA from its residential solar lease portfolio — a business model where Spruce acquires existing solar lease contracts on homes and earns recurring revenue from homeowner electricity savings. The positive net income is a milestone for a company that has carried going concern disclosures related to near-term debt maturities, and the EBITDA improvement suggests the underlying solar asset performance is sound. The going concern disclosure reflects a capital structure risk — specifically whether the company can refinance or retire debt maturities without dilutive equity raises — rather than operational deterioration in the solar assets themselves.

The contrasting narratives in this Q2 2026 earnings cluster — Staar Surgical's exceptional growth driven by Asia optics demand and Spruce Power's balance sheet repair through improving operations — reflect two distinct risk-reward profiles within US small and mid-cap equities. Staar's China dependency is a growth accelerator in an up-cycle but creates a single-country concentration risk if Chinese medical device regulatory frameworks tighten or if domestic Chinese competitors successfully qualify competing lenses. Spruce Power's trajectory from going concern risk to operational recovery, if sustained through debt refinancing, could re-rate the equity significantly from distressed levels. Both situations require patient capital and a tolerance for binary outcome distributions.

Synthesized from 14 sources.